M&A Deal Summary |
|
|---|---|
| Date | 2015-10-02 |
| Target | Pragma Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Vernalis |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1988 |
| Sector | Life Science |
| Employees | 115 |
| Revenue | 21M GBP (2017) |
Vernalis is a commercial stage pharmaceutical company with three marketed products; Tuzistra® XR in the US prescription cough cold market, Moxatag®, a once-a-day formulation of the antibiotic amoxicillin, also for the US prescription market, and frovatriptan an acute treatment for migraine. Vernalis was founded in 1988 and is based in Winnersh, United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| State: New York M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2015 M&A | 1 of 1 |